These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 31554632)

  • 1. Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment.
    Nahum Y; Mimouni M; Livny E; Bahar I; Hodak E; Leshem YA
    Br J Ophthalmol; 2020 Jun; 104(6):776-779. PubMed ID: 31554632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and Characteristics of Dupilumab-Induced Ocular Surface Disease in Adults With Atopic Dermatitis.
    Felfeli T; Georgakopoulos JR; Jo CE; Mimouni M; Piguet V; Drucker AM; Yeung J; Chan CC
    Cornea; 2022 Oct; 41(10):1242-1247. PubMed ID: 34843182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dupilumab induced ocular surface disease: A prospective case series.
    Pradhan SP; Sadiq SN; Cartes C; Babakinejad P; Ball S; Reynolds NJ; Meggitt S; Figueiredo FC
    Eur J Ophthalmol; 2024 May; 34(3):691-699. PubMed ID: 37644849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review.
    Neagu N; Dianzani C; Avallone G; Dell'Aquila C; Morariu SH; Zalaudek I; Conforti C
    J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):820-835. PubMed ID: 35122335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tacrolimus ointment in the management of atopic keratoconjunctivitis].
    Benaim D; Tétart F; Bauvin O; Delcampe A; Joly P; Muraine M; Gueudry J
    J Fr Ophtalmol; 2019 May; 42(5):435-440. PubMed ID: 30935698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of tacrolimus ointment combined with dupilumab for patients with atopic dermatitis in real-world clinical practice.
    Matsutani M; Imai Y; Inoue Y; Nakatani-Kusakabe M; Natsuaki M; Yamanishi K; Kanazawa N
    J Dermatol; 2021 Oct; 48(10):1564-1568. PubMed ID: 34155694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus ointment in the management of atopic keratoconjunctivitis.
    Benaim D; Tétart F; Bauvin O; Delcampe A; Joly P; Muraine M; Gueudry J
    J Fr Ophtalmol; 2019 Apr; 42(4):e147-e151. PubMed ID: 30851973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrolimus ointment vs steroid ointment for eyelid dermatitis in patients with atopic keratoconjunctivitis.
    Nivenius E; van der Ploeg I; Jung K; Chryssanthou E; van Hage M; Montan PG
    Eye (Lond); 2007 Jul; 21(7):968-75. PubMed ID: 16680103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.
    Liberman P; Shifera AS; Berkenstock M
    Cornea; 2020 Jun; 39(6):784-786. PubMed ID: 31985517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two cases of dupilumab-associated conjunctivitis with high expression of IL-8 mRNA on the ocular surface: a case report.
    Adachi R; Shoji J; Hirota A; Tomioka A; Tonozuka Y; Inada N; Yamagami S
    Allergy Asthma Clin Immunol; 2022 Oct; 18(1):89. PubMed ID: 36184619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ocular symptoms associated with dupilumab in atopic dermatitis].
    Voorberg AN; Oosterhaven JAF; Wijdh RHJ; de Bruin-Weller MS; Schuttelaar MLA
    Ned Tijdschr Geneeskd; 2019 Mar; 163():. PubMed ID: 30945835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial.
    Doss N; Reitamo S; Dubertret L; Fekete GL; Kamoun MR; Lahfa M; Ortonne JP
    Br J Dermatol; 2009 Aug; 161(2):427-34. PubMed ID: 19416227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of tacrolimus ointment in pediatric Patients with moderate to severe atopic dermatitis.
    Singalavanija S; Noppakun N; Limpongsanuruk W; Wisuthsarewong W; Aunhachoke K; Chunharas A; Wananukul S; Akaraphanth R
    J Med Assoc Thai; 2006 Nov; 89(11):1915-22. PubMed ID: 17205874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Upadacitinib on Atopic Keratoconjunctivitis Exacerbated by Dupilumab Treatment in Atopic Dermatitis Patients: A Prospective Dermatological and Ophthalmological Clinical Evaluation in Common Clinical Practice.
    Paganini C; Spelta S; Tofani L; Talamonti M; Bianchi L; Coassin M; Di Zazzo A; Galluzzo M
    J Clin Med; 2024 Jun; 13(13):. PubMed ID: 38999383
    [No Abstract]   [Full Text] [Related]  

  • 15. Multicenter prospective observational study of dupilumab-induced ocular events in atopic dermatitis patients.
    Costedoat I; Wallaert M; Gaultier A; Vasseur R; Vanhaecke C; Viguier M; Cordelette C; Denoyer A; Ferrier le Bouëdec MC; Coutu A; Lamiaux M; Tran THC; Lacour JP; Elmaleh V; Tetart F; Gueudry J; Tauber M; Giordano-Labadie F; Cassagne M; Nosbaum A; Ouilhon C; Jachiet M; Tadayoni R; Dezoteux F; Staumont-Salle D; Bouleau J; Labalette P; Doan S; Soria A; Mortemousque B; Seneschal J; Barbarot S;
    J Eur Acad Dermatol Venereol; 2023 May; 37(5):1056-1063. PubMed ID: 36732052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-related utility among adults with atopic dermatitis treated with 0.1% tacrolimus ointment as maintenance therapy over the long term: findings from the Protopic CONTROL study.
    Poole CD; Chambers C; Sidhu MK; Currie CJ
    Br J Dermatol; 2009 Dec; 161(6):1335-40. PubMed ID: 19754867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study.
    Johansson EK; Ivert LU; Bradley B; Lundqvist M; Bradley M
    BMC Dermatol; 2020 Sep; 20(1):8. PubMed ID: 32962676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial.
    Reitamo S; Harper J; Bos JD; Cambazard F; Bruijnzeel-Koomen C; Valk P; Smith C; Moss C; Dobozy A; Palatsi R;
    Br J Dermatol; 2004 Mar; 150(3):554-62. PubMed ID: 15030341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe atopic dermatitis: Dupilumab is not just safer, but more efficient.
    Giavina-Bianchi M; Rizzo LV; Giavina-Bianchi P
    Allergol Immunopathol (Madr); 2020; 48(6):792-797. PubMed ID: 32249095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records.
    Wang C; Kraus CN; Patel KG; Ganesan AK; Grando SA
    Int J Dermatol; 2020 Feb; 59(2):253-256. PubMed ID: 31286499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.